Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceu (NQ: RARE )

37.28 -1.06 (-2.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 590,868
Open 38.34
Bid (Size) 37.06 (1)
Ask (Size) 37.63 (1)
Prev. Close 38.34
Today's Range 37.20 - 38.87
52wk Range 33.36 - 85.53
Shares Outstanding 70,216,689
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via Globe NewsWire
Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
Dr. Camille Bedrosian to continue employment as strategic development advisor with the company 
From Ultragenyx Pharmaceutical Inc.
Via Globe NewsWire

Performance

YTD
-18.10%
-18.10%
1 Month
-18.07%
-18.07%
3 Month
-15.48%
-15.48%
6 Month
-15.43%
-15.43%
1 Year
-47.33%
-47.33%

More News

Read More
Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via Globe NewsWire
Where Ultragenyx Pharmaceutical Stands With Analysts
Via Benzinga
Earnings Scheduled For February 16, 2023
Via Benzinga
Earnings Preview: Ultragenyx Pharmaceutical
Via Benzinga
Analyst Expectations for Ultragenyx Pharmaceutical's Future
Via Benzinga
Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via Globe NewsWire
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via Globe NewsWire
Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones
From Ultragenyx Pharmaceutical Inc.
Via Globe NewsWire
The Latest Analyst Ratings for Ultragenyx Pharmaceutical
Via Benzinga
Analyst Expectations for Ultragenyx Pharmaceutical's Future
Via Benzinga
Where Ultragenyx Pharmaceutical Stands With Analysts
Via Benzinga
Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via Globe NewsWire
What You Missed On Wall Street On Friday
Via Talk Markets
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via Globe NewsWire
Ultragenyx to Present at Piper Sandler Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via Globe NewsWire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via Globe NewsWire
Ultragenyx Announces Departure of Chief Financial Officer
From Ultragenyx Pharmaceutical Inc.
Via Globe NewsWire
Ultragenyx to Present at Upcoming Healthcare Conferences
From Ultragenyx Pharmaceutical Inc.
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022
Via Benzinga
Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via Globe NewsWire
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Earnings Scheduled For November 2, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.